Oncology
FDA approves Servier Pharmaceuticals’ new MDS therapy
October 25, 2023Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes
The US Food and Drug Administration (FDA) has announced that it has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) for the treatment …
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
First patient dosed in Transgene and BioInvent’s phase 1 trial
October 10, 2023Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
BMS acquires Mirati Therapeutics for $4.8bn
October 9, 2023Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …
Eli Lilly to acquire POINT Biopharma
October 4, 2023Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …
FDA grants marketing authorisation to DNA test for predisposition to certain cancers
October 2, 2023Research and Development FDA, Invitae, Oncology, cancer testing, oncology
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the Invitae Common Hereditary Cancers Panel, …
Kura Oncology shares preclinical data for NSCLC treatment
September 29, 2023Medical Communications Kura Oncology, NSCLC, Oncology, oncology
Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 in …
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial
September 22, 2023Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …
EC approves Menarini Group’s Orserdu for breast cancer treatment
September 21, 2023Medical Communications European Commission, Oncology, Orserdu, breast cancer
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …
Exscientia enters AI drug discovery collaboration with Merck KGaA
September 20, 2023Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …
Nuvectis Pharma initiates phase 1a NXP900 clinical trial
September 13, 2023Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …
AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
September 11, 2023Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …
Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase
September 6, 2023Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase
Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023Medical Communications AstraZeneca, CLL, China, Oncology, SLL
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
Latest content
FibroFind appoints Lee Borthwick as CEO
